Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease
暂无分享,去创建一个
[1] J. W. Papez. A PROPOSED MECHANISM OF EMOTION , 1937 .
[2] D. Benson,et al. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. , 1983, Archives of neurology.
[3] R H Huesman,et al. Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose , 1983, Journal of computer assisted tomography.
[4] N. Foster,et al. Alzheimer's disease , 1983, Neurology.
[5] Luigi Mansi,et al. Cortical abnormalities in Alzheimer's disease , 1984, Annals of neurology.
[6] J. Haxby,et al. Brain Imaging: Aging and Dementia , 1984 .
[7] D. Kuhl. Imaging local brain function with emission computed tomography. , 1984, Radiology.
[8] G. V. Van Hoesen,et al. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.
[9] E. Metter,et al. Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's disease. , 1985, Research publications - Association for Research in Nervous and Mental Disease.
[10] J. Haxby,et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease , 1985, Annals of neurology.
[11] Robert P. Friedland,et al. Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization , 1985, Neuroscience Letters.
[12] W. Jagust,et al. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. , 1985, The American journal of psychiatry.
[13] J. Haxby,et al. Positron emission tomography in Alzheimer's disease , 1986, Neurology.
[14] B. L. Beattie,et al. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[15] G. di Chiro,et al. Dominantly inherited Alzheimer's disease: cerebral glucose metabolism. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[16] J. Becker,et al. Cognitive deficits and clinical diagnosis of Alzheimer's disease , 1987, Neurology.
[17] J. Growdon,et al. Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity. , 1988, Archives of neurology.
[18] J. Haxby,et al. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. , 1990, Journal of psychiatric research.
[19] B. L. Beattie,et al. 18Fluorodeoxyglucose Positron Emission Tomography Studies in Presumed Alzheimer Cases, Including 13 Serial Scans , 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[20] J. Haxby,et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. , 1990, Archives of neurology.
[21] Karl Herholz,et al. Criteria for the Diagnosis of Alzheimer's Disease with Positron Emission Tomography , 1990 .
[22] Functional Brain Imaging and Alzheimer-Type Dementia , 1991, Alzheimer disease and associated disorders.
[23] E K Warrington,et al. Selective impairment of memory and visual perception in splenial tumours. , 1991, Brain : a journal of neurology.
[24] K. Herholz,et al. Abnormalities of Energy Metabolism in Alzheimer's Disease Studied with PET a , 1991, Annals of the New York Academy of Sciences.
[25] G Blomqvist,et al. Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[26] M. Corbetta,et al. Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[27] K. Herholz,et al. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type , 1992, Neurobiology of Aging.
[28] G D Pearlson,et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. , 1992, Archives of general psychiatry.
[29] S Minoshima,et al. An automated method for rotational correction and centering of three-dimensional functional brain images. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] N Butters,et al. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.
[31] M J de Leon,et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.
[32] M. Mintun,et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[34] T. Iwatsubo,et al. Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease , 1994, The Lancet.
[35] K. Fukushi,et al. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo. , 1994, Nuclear medicine and biology.
[36] Satoshi Minoshima,et al. Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.
[37] K. Weisgraber. Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.
[38] R. Koeppe,et al. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] Giovanni B. Frisoni,et al. Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late‐onset alzheimer's disease , 1995 .
[40] P M Grasby,et al. Brain systems for encoding and retrieval of auditory-verbal memory. An in vivo study in humans. , 1995, Brain : a journal of neurology.
[41] H. Soininen,et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ϵ4 allele , 1995, Neurology.
[42] J C Mazziotta,et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.
[43] A. Smith,et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease , 1995, Neuroscience.
[44] H. Braak,et al. Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.
[45] R. Koeppe,et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[46] K Kontula,et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.
[47] N. Foster,et al. Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.
[48] H. Hoshi,et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] R. Albin,et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.
[50] K. Ishii,et al. Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] H. Soininen,et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[52] B T Hyman,et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.
[53] J. Morris,et al. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.
[54] S. Corkin,et al. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.
[55] S. Thibodeau,et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.
[56] D J Wyper,et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. , 1996, Journal of psychiatric research.
[57] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.
[58] C. Frith. Principles and methods , 1997 .
[59] Akira Homma,et al. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ϵ4 allele , 1997, Neuroscience Letters.
[60] T G Turkington,et al. Selective and divided visual attention: Age‐related changes in regional cerebral blood flow measured by H215O PET , 1997, Human brain mapping.
[61] C. Jack,et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.
[62] N. Foster,et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.
[63] Yaakov Stern,et al. The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease , 1997, Annals of neurology.
[64] A. Asaka,et al. Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians. , 1997, Human heredity.
[65] K. Ishii,et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] L. Wahlund,et al. MRI-guided SPECT-measurements of medial temporal lobe blood flow in Alzheimer's disease , 1997, Psychiatry Research: Neuroimaging.
[67] S. Scheff,et al. Time Course of Changes in Lactate and Free Fatty Acids after Experimental Brain Injury and Relationship to Morphologic Damage , 1997, Experimental Neurology.
[68] E. Corder,et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. , 1997, Archives of neurology.
[69] K. Ishii,et al. Lack of Association of Apolipoprotein E ε4 Allele Dose with Cerebral Glucose Metabolism in Alzheimer Disease , 1998 .
[70] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[71] Jonathan D. Cohen,et al. Reproducibility of fMRI Results across Four Institutions Using a Spatial Working Memory Task , 1998, NeuroImage.
[72] J. Baron,et al. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. , 1998, Brain : a journal of neurology.
[73] Daniel B Hier,et al. Visual Form of Alzheimer's Disease and Its Response to Anticholinesterase Therapy , 1998, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[74] K. Ishii,et al. Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[75] H. Soininen,et al. Longitudinal SPECT study in Alzheimer’s disease: relation to apolipoprotein E polymorphism , 1998, Journal of neurology, neurosurgery, and psychiatry.
[76] G. Alexander,et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.
[77] Steven D. Edland,et al. Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.
[78] E. Mandelkow,et al. Tau in Alzheimer's disease. , 1998, Trends in cell biology.
[79] M. Macavoy,et al. Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease. , 1998, Archives of neurology.
[80] R. Mohs,et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. , 1998, Archives of internal medicine.
[81] B L Holman,et al. Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.
[82] G. Wilcock,et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.
[83] S. Minoshima,et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease , 1999, Neurology.
[84] A. Hofman,et al. Apolipoprotein E genotype and progression of Alzheimer’s disease: the Rotterdam Study , 1999, Journal of Neurology.
[85] G Mariani,et al. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[86] J. Baron,et al. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. , 1999, Brain : a journal of neurology.
[87] J. Hodges,et al. Attention and executive deficits in Alzheimer's disease. A critical review. , 1999, Brain : a journal of neurology.
[88] J. Wegiel,et al. MRI of entorhinal cortex in mild Alzheimer's disease , 1999, The Lancet.
[89] A W Toga,et al. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.
[90] J. Mazziotta,et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[91] R T Staff,et al. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy , 2000, Nuclear medicine communications.
[92] K. Beyreuther,et al. Prospects for pharmacological intervention in Alzheimer disease. , 2000, Archives of neurology.
[93] S. Tanada,et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.
[94] K Ball,et al. Visual attention impairments in Alzheimer’s disease , 2000, Neurology.
[95] R. Koeppe,et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex , 2000, Annals of neurology.
[96] F. Craik,et al. The Effect of Divided Attention on Encoding and Retrieval in Episodic Memory Revealed by Positron Emission Tomography , 2000, Journal of Cognitive Neuroscience.
[97] T. Ohnishi,et al. Longitudinal Evaluation of Early Alzheimer's Disease Using Brain Perfusion Spect the Recruitment Was For , 2000 .